ArticleJournal of burn care & research : official publication of the American Burn Association2026
Reduced Mortality with Use of Point of Care Cell Suspension Autograft.
Article in Journal of burn care & research : official publication of the American Burn Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell suspension autograft (CSA) is a non-cultured, autologous cellular suspension used in partial-thickness burns or as an adjunct to widely meshed split-thickness skin grafts (STSGs). While CSA has been shown to improve patient outcomes in burn care, literature is limited in highlighting its impact on mortality when used in combination with STSG. This retrospective, matched, case-control study investigates the clinical efficacy of CSA in adult patients with burn injuries admitted to a regional burn center from 2015 to 2023. Patients treated with CSA and STSG (n = 63, "CSA-treated") were compared against patients treated with STSG alone (n = 126, "non-CSA-treated"). Non-CSA-treated patients were matched in a 2:1 fashion to CSA-treated patients based on third-degree burned TBSA and age. Outcomes included mortality, length of stay (LOS), intensive care unit LOS (ICU LOS), and number of procedures. Multivariate analyses revealed that CSA-treated patients had a significant reduction in mortality (P = .0445) and a 78.9% reduction in odds of death (OR: 0.211) compared to non-CSA-treated patients. Cell suspension autograft-treated patients displayed nonsignificant increases in LOS (P = .0670), ICU LOS (P = .0851), and number of procedures (P = .9084). Selection and chronology bias may partially account for the improved mortality in the CSA-treated group. The nonsignificant increases in LOS, ICU LOS, and number of procedures may be reflective of increased survivorship. These findings demonstrate that CSA enhances survival in patients with burn injuries when used with STSG, warranting further research to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.